<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38970">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599064</url>
  </required_header>
  <id_info>
    <org_study_id>RXI-109-1501</org_study_id>
    <nct_id>NCT02599064</nct_id>
  </id_info>
  <brief_title>Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD</brief_title>
  <official_title>A Phase 1/2 Multicenter, Multidose, Dose Escalation Study to Evaluate the Safety, Tolerability and Clinical Activity of RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects With Advanced Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RXi Pharmaceuticals, Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RXi Pharmaceuticals, Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and clinical activity of RXI-109
      administered by intravitreal injection to reduce the progression of subretinal fibrosis in
      subjects with advanced neovascular age-related macular degeneration (NVAMD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the safety, tolerability and pharmacokinetics (PK) of single and multiple doses of
      RXI-109 when administered by intravitreal injection. Evaluate the clinical activity of
      single and multiple doses of RXI-109 when administered by intravitreal injection. Study
      participation is intended to be seven months from time of initial treatment with RXI-109.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, severity and relationship of AEs</measure>
    <time_frame>Seven (7) months</time_frame>
    <description>Assess severity and frequency of reported adverse events graded by CTCAE, ophthalmological exams to assess clinically relevant changes in ocular health, clinically-relevant changes in physical exams or laboratory testing assessed by medical personnel, and monitoring for any change in best corrected visual acuity (BCVA)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of RXI-109 by intravitreal injection following single and multiple doses</measure>
    <time_frame>Four (4) months</time_frame>
    <description>Determine peak whole blood concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of RXI-109 by intravitreal injection following single and multiple doses</measure>
    <time_frame>Four (4) months</time_frame>
    <description>Determine area under the whole blood concentration versus time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of RXI-109 by intravitreal injection following single and multiple doses</measure>
    <time_frame>Four (4) months</time_frame>
    <description>Determine drug half-life in whole blood (T1/2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the clinical activity of RXI-109</measure>
    <time_frame>Seven (7) months</time_frame>
    <description>Evaluate the clinical activity of RXI-109 to reduce the formation or progression of subretinal fibrosis by assessing changes in lesion(s) by standard ophthalmological testing including optical coherence tomography (OCT) and fluorescein angiography (FA), and changes in best corrected visual acuity (BCVA)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">9</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <condition>Subfoveal Choroidal Neovascularization</condition>
  <condition>Subretinal Scarring</condition>
  <condition>Subretinal Fibrosis</condition>
  <arm_group>
    <arm_group_label>RXI-109</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravitreal injections of RXI-109 in one eye given on Day 1 and at monthly intervals through Month 3 for a total of four doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RXI-109</intervention_name>
    <description>RXI-109 dosed intravitreally to subjects with NVAMD</description>
    <arm_group_label>RXI-109</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects presenting with advanced NVAMD in the study eye with BCVA ≤20/100
             potentially due to subretinal fibrosis involving the fovea

          -  BCVA ≥20/800 in the contralateral eye and better than the study eye

          -  ≥50 years of age

          -  Subfoveal choroidal neovascularization (CNV) of any type

        Exclusion Criteria:

          -  Presence of other causes of CNV including pathologic myopia, ocular histoplasmosis
             syndrome, angioid streaks, choroidal rupture, and multifocal choroiditis

          -  Evidence of inflammation (Grade 1 or higher) in the anterior or posterior chamber
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pamela A Pavco, PhD</last_name>
    <role>Study Director</role>
    <affiliation>RXi Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Manager</last_name>
    <email>clinicaloperations@rxipharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 3, 2016</lastchanged_date>
  <firstreceived_date>November 3, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>RXI-109</keyword>
  <keyword>NVAMD</keyword>
  <keyword>Retinal scarring</keyword>
  <keyword>Subretinal scarring</keyword>
  <keyword>Retinal fibrosis</keyword>
  <keyword>Subretinal fibrosis</keyword>
  <keyword>Eye diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
